Cancer Immunology, Immunotherapy

, Volume 59, Issue 4, pp 629–633 | Cite as

Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells

  • Zoran Popmihajlov
  • Fabio R. Santori
  • Daniel Gebreselassie
  • Anthony D. Sandler
  • Stanislav Vukmanovic
Short Communication
First Online:
Received:
Accepted:

Abstract

High avidity for antigen and diversity of T cell receptor (TCR) repertoire are essential for effective immunity against cancer. We have previously created a transgenic mouse strain with increased TCR avidity in a diverse T cell population. In this report, we show that strong alloreactive responses of transgenic T cells against targets with low MHC class I expression can be used for effective adoptive transfer of tumor immunity in vivo. Alloreactive transgenic T cells could be an effective therapeutic approach counteracting tumor evasion of the immune system.

Keywords

T cells Adoptive therapy Alloreactivity 

Abbreviations

TCR

T cell receptor

TAP

Transporter associated with antigen processing

WT

Wild type

This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported by the NIH grants AI48837 and AI41573 to SV. ZP performed all in vivo and some in vitro experiments. FRS participated in in vivo and performed some in vitro experiments. DG performed mass spectrometry analysis. ADS participated in the data analysis and manuscript writing. SV designed the study and participated in manuscript writing.

Conflict of interest statement

ZP, FRS and SV are authors of a provisional patent application related to the work presented here and this may be perceived as conflict of interest.

References

  1. 1.
    Rosenberg SA et al (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299–308CrossRefPubMedGoogle Scholar
  2. 2.
    Schumacher TN, Restifo NP (2009) Adoptive T cell therapy of cancer. Curr Opin Immunol 21(2):187–189CrossRefPubMedGoogle Scholar
  3. 3.
    Zeh HJI et al (1999) High avidity CTLs for two self antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162:989–994PubMedGoogle Scholar
  4. 4.
    Van den Eynde BJ, Boon T (1997) Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 27(2):81–86CrossRefPubMedGoogle Scholar
  5. 5.
    Bouneaud C, Kourilsky P, Bousso P (2000) Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13:829–840CrossRefPubMedGoogle Scholar
  6. 6.
    Stauss HJ (1999) Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 20:180–183CrossRefPubMedGoogle Scholar
  7. 7.
    Stauss HJ et al (2004) Exploiting alloreactivity for tumour immunotherapy. Vox Sang 87(Suppl 2):227–229CrossRefPubMedGoogle Scholar
  8. 8.
    Kolb HJ (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112(12):4371–4383CrossRefPubMedGoogle Scholar
  9. 9.
    Childs R et al (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343(11):750–758CrossRefPubMedGoogle Scholar
  10. 10.
    Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3(11):999–1005CrossRefPubMedGoogle Scholar
  11. 11.
    Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56:227–236CrossRefPubMedGoogle Scholar
  12. 12.
    Garcia-Lora A et al (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 106(4):521–527CrossRefPubMedGoogle Scholar
  13. 13.
    Vago L et al (2009) Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 361(5):478–488CrossRefPubMedGoogle Scholar
  14. 14.
    van Hall T et al (2006) Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 12(4):417–424CrossRefPubMedGoogle Scholar
  15. 15.
    Santori FR et al (2007) TCRβ chain that forms peptide-independent alloreactive TCR transfers reduced reactivity with irrelevant peptide/MHC complex. J Immunol 178:6109–6114PubMedGoogle Scholar
  16. 16.
    Stojakovic M et al (2008) Adaptable TCR avidity thresholds for negative selection. J Immunol 181:6770–6778PubMedGoogle Scholar
  17. 17.
    Nesic D et al (2002) Factors influencing the patterns of T lymphocyte allorecognition. Transplantation 73:797–803CrossRefPubMedGoogle Scholar
  18. 18.
    Gebreselassie D, Spiegel H, Vukmanovic S (2006) Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides. Hum Immunol 67:894–906CrossRefPubMedGoogle Scholar
  19. 19.
    Balendiran GK et al (1997) The three-dimensional structure of an H-2Ld-peptide complex explains the unique interaction of Ld with beta-2 microglobulin and peptide. Proc Natl Acad Sci USA 94(13):6880–6885CrossRefPubMedGoogle Scholar
  20. 20.
    Udaka K et al (1993) A ubiquitous protein is the source of naturally occurring peptides that are recognized by a CD8+ T-cell clone. Proc Natl Acad Sci USA 90:11272–11276CrossRefPubMedGoogle Scholar
  21. 21.
    Uenaka A et al (1994) Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene. J Exp Med 180:1599–1607CrossRefPubMedGoogle Scholar
  22. 22.
    Sabatino DE et al (2005) Identification of mouse AAV capsid-specific CD8 + T cell epitopes. Mol Ther 12(6):1023–1033CrossRefPubMedGoogle Scholar
  23. 23.
    Kearney ER et al (1994) Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1(4):327–339CrossRefPubMedGoogle Scholar
  24. 24.
    Kruger T et al (2005) Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 54:826–836CrossRefPubMedGoogle Scholar
  25. 25.
    Sandberg JK, Karre K, Glas R (1999) Recognition of the major histocompatibility complex restriction element modulates CD8+ T cell specificity and compensates for loss of T cell receptor contacts with the specific peptide. J Exp Med 189:883–893CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Zoran Popmihajlov
    • 1
    • 5
  • Fabio R. Santori
    • 1
    • 4
  • Daniel Gebreselassie
    • 2
    • 3
  • Anthony D. Sandler
    • 2
  • Stanislav Vukmanovic
    • 1
    • 2
  1. 1.Michael Heidelberger Division of Immunology, Department of Pathology and NYU Cancer CenterNYU School of MedicineNew YorkUSA
  2. 2.Center for Cancer and Immunology Research, Children’s Research InstituteChildren’s National Medical CenterWashingtonUSA
  3. 3.Lombardi Comprehensive Cancer CenterGeorgetown University Medical CenterWashingtonUSA
  4. 4.Department of Pathology, Skirball Institute for Molecular Medicine, NYU Cancer CenterNYU School of MedicineNew YorkUSA
  5. 5.Division of Immunology, Department of MedicineWeill Medical College of Cornell UniversityNew YorkUSA

Personalised recommendations